Oncocyte Corp (NASDAQ:IMDX - Get Free Report) major shareholder Broadwood Partners, L.P. acquired 40,114 shares of the firm's stock in a transaction on Friday, April 17th. The shares were bought at an average cost of $3.57 per share, for a total transaction of $143,206.98. Following the completion of the acquisition, the insider owned 12,074,010 shares of the company's stock, valued at approximately $43,104,215.70. This represents a 0.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Broadwood Partners, L.P. also recently made the following trade(s):
- On Monday, April 20th, Broadwood Partners, L.P. acquired 40,690 shares of Oncocyte stock. The shares were bought at an average cost of $3.88 per share, for a total transaction of $157,877.20.
- On Thursday, April 16th, Broadwood Partners, L.P. acquired 102,057 shares of Oncocyte stock. The shares were bought at an average cost of $3.45 per share, for a total transaction of $352,096.65.
- On Tuesday, February 10th, Broadwood Partners, L.P. acquired 521,739 shares of Oncocyte stock. The shares were bought at an average cost of $5.75 per share, for a total transaction of $2,999,999.25.
Oncocyte Trading Up 3.9%
IMDX opened at $3.99 on Tuesday. The stock has a market capitalization of $128.36 million, a P/E ratio of -2.46 and a beta of 1.52. Oncocyte Corp has a 52-week low of $2.33 and a 52-week high of $8.51. The firm's fifty day moving average is $4.57.
Oncocyte (NASDAQ:IMDX - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.27) earnings per share (EPS) for the quarter. The business had revenue of $1.14 million for the quarter.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Oncocyte in a research report on Friday, March 27th. Wall Street Zen downgraded Oncocyte from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Finally, Lake Street Capital raised their price target on shares of Oncocyte from $8.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $12.00.
Check Out Our Latest Stock Report on Oncocyte
Oncocyte Company Profile
(
Get Free Report)
Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.
Oncocyte's product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
